Loading clinical trials...
Loading clinical trials...
A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Conditions
Interventions
rilzabrutinib
Locations
20
United States
University of Michigan Health - Michigan Medicine - University Hospital-Investigational Site Number: 8400001
Ann Arbor, Michigan, United States
Mayo Clinic_Investigational Site Number: 8400009
Rochester, Minnesota, United States
New York Oncology Hematology_Investigational Site Number: 8400010
Albany, New York, United States
Montefiore Medical Center-Investigational Site Number: 8400012
The Bronx, New York, United States
Community Cancer Trials of Utah_Investigational Site Number: 8400002
Ogden, Utah, United States
Investigational Site Number : 0400001
Vienna, Austria
Start Date
October 24, 2025
Primary Completion Date
November 5, 2027
Completion Date
December 30, 2028
Last Updated
April 3, 2026
NCT05070845
NCT07039422
NCT07104565
NCT07362199
NCT07362238
NCT07294365
Trial Transparency email recommended (Toll free for US & Canada)
CONTACT
800-633-1610contact-us@sanofi.comLead Sponsor
Sanofi
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions